American Journal of Cardiology
Volume 103, Issue 9 , Pages 1269-1274, 1 May 2009

Usefulness of Myeloperoxidase Levels in Healthy Elderly Subjects to Predict Risk of Developing Heart Failure

  • W.H. Wilson Tang, MD

      Affiliations

    • Department of Cell Biology, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
    • Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationCorresponding author: Tel: 216-444-2121; fax: 216-445-6165
    • ,
  • Ronit Katz, DPhil

      Affiliations

    • Collaborative Health Studies Coordinating Center, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington
    • ,
  • Marie-Luise Brennan, PhD

      Affiliations

    • Department of Cell Biology, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
    • Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Ronnier J. Aviles, MD

      Affiliations

    • Overlake Internal Medicine Associates, Bellevue, Washington
    • ,
  • Russell P. Tracy, PhD

      Affiliations

    • Department of Pathology, University of Vermont College of Medicine, Colchester, Vermont
    • ,
  • Bruce M. Psaty, MD, PhD

      Affiliations

    • Department of Medicine, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington
    • Department of Epidemiology, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington
    • Department of Health Services, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington
    • Center for Health Studies, Group Health, Seattle, Washington
    • ,
  • Stanley L. Hazen, MD, PhD

      Affiliations

    • Department of Cell Biology, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
    • Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio

Received 14 November 2008; received in revised form 13 January 2009; accepted 13 January 2009. published online 16 March 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This work was supported by Grants No. P01 HL076491-055328, HL077107-050004, and P01 HL087018-020001 from the National Institutes of Health, Bethesda, Maryland, and contracts previously supporting development of the Cardiovascular Health Study, including N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, and U01 HL080295 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland, with additional contribution from the National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. Drs. Hazen and Tang were supported by Grant No. 1UL1RR024989 from the National Institutes of Health. Dr. Tang reports having received research grant support and honorarium from Abbott Laboratories. Dr. Hazen is named as co-inventor on pending and issued patents filed by the Cleveland Clinic that relate to the use of biomarkers in inflammatory and cardiovascular disease; reports he is the scientific founder of PrognostiX Inc.; has received speaking honoraria from Pfizer, AstraZeneca, Merck, Merck Schering Plough, BioSite, Lilly, Wyeth, and Abbott; has received research grant support from Abbott Diagnostics, Pfizer, Merck, PrognostiX Inc., Hawaii Biotech, ArgiNOx, Sanofi, and Takeda; and has received consulting fees from Abbott Laboratories, Pfizer, PrognostiX Inc., Wyeth, BioPhysical, and AstraZeneca.

PII: S0002-9149(09)00120-9

doi:10.1016/j.amjcard.2009.01.026

American Journal of Cardiology
Volume 103, Issue 9 , Pages 1269-1274, 1 May 2009

Article Tools

* Image Usage & Resolution